Modular Medical's Losses Widen Amid R&D Surge, Cash Drains

Ticker: MODD · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 1074871

Sentiment: bearish

Topics: Medical Devices, Insulin Pumps, Going Concern, Cash Burn, FDA Clearance, Pre-revenue, Biotechnology

Related Tickers: MODD, PODD, TNDM

TL;DR

**MODD is bleeding cash and faces a 'going concern' warning; steer clear until they prove commercial viability.**

AI Summary

Modular Medical, Inc. (MODD) reported a net loss of $6.702 million for the three months ended June 30, 2025, a significant increase from the $4.137 million net loss in the same period last year, reflecting heightened operating expenses. Research and development expenses surged to $5.134 million from $3.205 million, while selling, general, and administrative expenses rose to $1.670 million from $1.015 million. The company's cash and cash equivalents decreased substantially to $7.522 million as of June 30, 2025, from $13.095 million on March 31, 2025, primarily due to $5.372 million in net cash used in operating activities and $934,000 in investing activities. Despite these losses, MODD raised $728,000 from an at-the-market stock sale in June 2025 and $11.367 million from private placements in March 2025. The company received FDA clearance for its MODD1 insulin pump in September 2024 and expects initial shipments by October 2025, with plans to replace it with an updated 'Pivot' version pending further FDA approval. The filing explicitly states substantial doubt about the company's ability to continue as a going concern due to its pre-revenue status and ongoing operating losses.

Why It Matters

This 10-Q reveals Modular Medical is burning through cash rapidly, with a significant increase in net loss and a substantial decline in cash reserves. For investors, the 'going concern' warning is a critical red flag, indicating high financial risk despite recent capital raises. Employees face uncertainty given the company's pre-revenue status and reliance on future financing. Customers awaiting the MODD1 pump might see potential delays or product strategy shifts if financial stability isn't achieved. In the competitive diabetes device market, MODD's financial fragility could hinder its ability to effectively launch and scale against established players like Insulet (PODD) or Tandem Diabetes Care (TNDM).

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' and reported a net loss of $6.702 million for the quarter, with cash and cash equivalents dropping from $13.095 million to $7.522 million in three months. This rapid cash burn and explicit going concern warning indicate a very high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider avoiding MODD stock until the company demonstrates a clear path to profitability and secures sufficient long-term funding. Monitor the commercial launch of the MODD1 and subsequent Pivot product for signs of revenue generation and market adoption, as these are critical for addressing the going concern risk.

Financial Highlights

debt To Equity
0.19
revenue
N/A
operating Margin
N/A
total Assets
$14.171M
total Debt
$2.328M
net Income
-$6.702M
eps
-$0.12
gross Margin
N/A
cash Position
$7.522M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Modular Medical, Inc.'s current financial health?

Modular Medical, Inc. is in a precarious financial state, reporting a net loss of $6.702 million for the three months ended June 30, 2025, and a significant decrease in cash and cash equivalents from $13.095 million to $7.522 million. The company explicitly states 'substantial doubt' about its ability to continue as a going concern.

When does Modular Medical expect to ship its MODD1 insulin pump?

Modular Medical, Inc. expects initial shipments of its MODD1 insulin pump by October 2025. The company received FDA clearance to market and sell the MODD1 in the United States in September 2024.

What are the primary risks for Modular Medical investors?

The primary risks for Modular Medical investors include the company's 'going concern' warning, its pre-revenue status, significant operating losses of $6.702 million, and rapid cash burn, which saw cash and cash equivalents decline by over $5.5 million in one quarter. The ability to raise additional capital on acceptable terms is also a major risk.

How much cash did Modular Medical raise recently?

Modular Medical, Inc. raised $728,000 from an at-the-market stock sale in June 2025 and approximately $11.367 million from private placements of common stock and warrants in March 2025.

What is the 'Pivot' product mentioned by Modular Medical?

The 'Pivot' is an updated version of Modular Medical's MODD1 insulin pump, described as a tubeless patch product that integrates the set. The company intends to replace the MODD1 with the Pivot product once it receives the required regulatory approval from the FDA.

Did Modular Medical's operating expenses increase?

Yes, Modular Medical's total operating expenses increased significantly to $6.804 million for the three months ended June 30, 2025, up from $4.220 million in the same period last year. This was driven by increases in both research and development and selling, general and administrative expenses.

What is the significance of the 'going concern' disclosure for Modular Medical?

The 'going concern' disclosure for Modular Medical indicates that management and its independent auditors have substantial doubt about the company's ability to continue operating for at least the next year without securing additional funding. This is a critical warning sign for investors regarding the company's long-term viability.

What regulatory approvals has Modular Medical received?

Modular Medical, Inc. received FDA clearance in September 2024 to market and sell its MODD1 insulin pump in the United States. The company is currently preparing a second 510(k) premarket notification application for its updated Pivot product.

How did Modular Medical's research and development spending change?

Modular Medical's research and development expenses increased substantially to $5.134 million for the three months ended June 30, 2025, compared to $3.205 million for the same period in 2024, reflecting a significant ramp-up in product development activities.

What is Modular Medical's strategy to expand the insulin pump market?

Modular Medical's strategy is to expand the wearable insulin delivery device market beyond highly motivated 'super users' into the mass market by simplifying and streamlining the user experience of its two-part patch pump, the MODD1, and its successor, the Pivot. This aims to alter the trade-offs between cost, complexity, and access to higher standards of care.

Risk Factors

Industry Context

Modular Medical operates in the highly competitive and regulated medical device industry, specifically focusing on diabetes management technology. The market is characterized by rapid innovation, significant R&D investment, and stringent FDA approval processes. Companies in this space often face long development cycles and substantial capital requirements before achieving profitability.

Regulatory Implications

The company's reliance on FDA clearance for its MODD1 pump and the upcoming 'Pivot' version presents significant regulatory risk. Delays or failures in obtaining or maintaining regulatory approval could severely impact revenue generation and future growth prospects.

What Investors Should Do

  1. Monitor cash burn and future financing needs.
  2. Evaluate the success of the MODD1 launch and 'Pivot' development.
  3. Assess the impact of rising operating expenses.
  4. Consider the going concern disclosure.

Key Dates

Glossary

Going Concern
An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. If substantial doubt exists, it must be disclosed. (The company explicitly states substantial doubt about its ability to continue as a going concern, highlighting significant financial risks.)
At-the-Market (ATM) Stock Sale
A method for public companies to sell shares of their stock directly into the open market over time, typically at prevailing market prices. (MODD raised $728,000 through this method in June 2025, indicating a need for capital.)
Accumulated Deficit
The cumulative net losses of a company since its inception, less any net gains. It represents a deficit in retained earnings. (MODD has a substantial accumulated deficit of $91.455 million as of June 30, 2025, reflecting its history of operating losses.)
Potentially Dilutive Securities
Financial instruments such as stock options, warrants, or convertible securities that could be converted into common stock, thereby increasing the total number of shares outstanding. (The presence of 25,313 thousand potentially dilutive securities indicates a future risk of dilution for current shareholders.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. (R&D expenses increased significantly to $5.134 million, showing increased investment in product development, but also contributing to higher net losses.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Modular Medical, Inc. has experienced a significant widening of its net loss, increasing from $4.137 million to $6.702 million. This deterioration is primarily driven by a substantial increase in operating expenses, with Research and Development costs rising from $3.205 million to $5.134 million and Selling, General, and Administrative expenses growing from $1.015 million to $1.670 million. Concurrently, the company's cash position has diminished considerably, falling from $13.095 million at the start of the fiscal year to $7.522 million by the end of the second quarter, reflecting an accelerated cash burn rate.

Filing Stats: 4,581 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2025-08-14 16:01:17

Key Financial Figures

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited): 1 Condensed Consolidated Balance Sheets as of June 30, 2025 and March 31, 2025 1 Condensed Consolidated Statements of Operations for the three months ended June 30, 2025 and June 30, 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three months ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2025 and 2024 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 18 Item 4.

Controls and Procedures

Controls and Procedures 18

— OTHER INFORMATION

PART II — OTHER INFORMATION 19 Item 1.

Legal Proceedings

Legal Proceedings 19 Item 1A.

Risk Factors

Risk Factors 19 Item 2. Unregistered Sales of Equity Securities 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 21

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Modular Medical, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value) June 30, 2025 (Unaudited) March 31, 2025 ASSETS CURRENT ASSETS Cash and cash equivalents $ 7,522 $ 13,095 Prepaid expenses and other 770 422 TOTAL CURRENT ASSETS 8,292 13,517 Property and equipment, net 5,212 4,453 Right of use asset, net 667 765 TOTAL ASSETS $ 14,171 $ 18,735 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 1,067 $ 338 Accrued expenses 546 504 Short-term lease liabilities 437 423 TOTAL CURRENT LIABILITIES 2,050 1,265 Long-term lease liabilities 278 393 TOTAL LIABILITIES 2,328 1,658 Commitments and Contingencies (Note 7) STOCKHOLDERS' EQUITY Preferred Stock, $ 0.001 par value, 5,000 shares authorized, none issued and outstanding — — Common Stock, $ 0.001 par value, 100,000 shares authorized; 55,275 and 53,706 shares issued and outstanding as of June 30, 2025 and March 31, 2025, respectively 55 54 Additional paid-in capital 103,243 101,776 Accumulated deficit ( 91,455 ) ( 84,753 ) TOTAL STOCKHOLDERS' EQUITY 11,843 17,077 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 14,171 $ 18,735 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Modular Medical, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Three Months Ended June 30, 2025 2024 Operating expenses Research and development $ 5,134 $ 3,205 Selling, general and administrative 1,670 1,015 Total operating expenses 6,804 4,220 Loss from operations ( 6,804 ) ( 4,220 ) Other income 102 83 Net loss $ ( 6,702 ) $ ( 4,137 ) Net loss per share Basic and diluted $ ( 0.12 ) $ ( 0.12 ) Shares used in computing net loss per share Basic and diluted 54,288 33,884 The accompanying notes are an integral part of these condensed

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing